secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001193805-25-000946
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)
--------------------------------------------------------------------------------

- Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.
- 15N-ureagenesis function (RUF) increased from 29.0% baseline to 43.7% at day 28 post-fifth dose (p=0.026).
- Ammonia remained stable and within normal range in both studies; one hyperammonemia event on placebo.
- ARCT-810 safe and well tolerated across Phase 1/2 with no serious infusion reactions on optimized 3-hour regimen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525000946/0001193805-25-000946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525000946/e664658_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-000946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer